Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) EVP Mark David Novara bought 532 shares of Tandem Diabetes Care stock in a transaction dated Friday, November 15th. The shares were acquired at an average price of $23.24 per share, with a total value of $12,363.68. Following the completion of the purchase, the executive vice president now directly owns 532 shares in the company, valued at $12,363.68. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Tandem Diabetes Care Price Performance
NASDAQ TNDM opened at $27.87 on Wednesday. Tandem Diabetes Care, Inc. has a 52-week low of $17.33 and a 52-week high of $53.69. The business has a 50 day simple moving average of $37.19 and a 200 day simple moving average of $41.62. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -14.44 and a beta of 1.36. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90.
Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $243.97 million during the quarter, compared to the consensus estimate of $224.14 million. During the same quarter in the prior year, the firm posted ($0.38) EPS. The firm's quarterly revenue was up 31.4% on a year-over-year basis. Analysts anticipate that Tandem Diabetes Care, Inc. will post -1.73 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tandem Diabetes Care
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold | Ad
Trump's back in the White House, but Wall Street is pissed.
Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.
A number of institutional investors have recently added to or reduced their stakes in the company. Fred Alger Management LLC grew its position in shares of Tandem Diabetes Care by 45.2% in the second quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company's stock valued at $87,595,000 after purchasing an additional 677,036 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Tandem Diabetes Care by 2,836.2% in the 2nd quarter. Victory Capital Management Inc. now owns 403,370 shares of the medical device company's stock valued at $16,252,000 after acquiring an additional 389,632 shares during the last quarter. Bellevue Group AG boosted its holdings in shares of Tandem Diabetes Care by 19.9% during the third quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company's stock worth $78,496,000 after purchasing an additional 307,624 shares during the period. Kingdon Capital Management L.L.C. lifted its position in shares of Tandem Diabetes Care by 153.9% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 493,080 shares of the medical device company's stock worth $17,460,000 after purchasing an additional 298,880 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $10,208,000.
Wall Street Analyst Weigh In
TNDM has been the subject of a number of analyst reports. The Goldman Sachs Group assumed coverage on Tandem Diabetes Care in a research report on Friday, October 4th. They issued a "neutral" rating and a $46.00 price target for the company. Wells Fargo & Company upped their price target on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. Morgan Stanley reiterated an "equal weight" rating and set a $45.00 target price on shares of Tandem Diabetes Care in a report on Monday, September 23rd. Barclays lifted their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an "overweight" rating in a research note on Friday, November 8th. Finally, Piper Sandler reissued an "overweight" rating and issued a $55.00 price objective (up from $50.00) on shares of Tandem Diabetes Care in a research note on Friday, August 2nd. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $54.25.
Read Our Latest Analysis on Tandem Diabetes Care
Tandem Diabetes Care Company Profile
(
Get Free Report)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
